Batten Disease Clinical Trial
Official title:
A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
Verified date | March 2023 |
Source | BioMarin Pharmaceutical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 144 weeks, in patients with CLN2. The study is designed to assess disease progression in CLN2 patients treated with BMN 190 compared to natural history data from untreated historical controls.
Status | Completed |
Enrollment | 14 |
Est. completion date | April 20, 2022 |
Est. primary completion date | April 20, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Years to 17 Years |
Eligibility | Enrollment over the age of 2 years is complete. Inclusion Criteria: - Diagnosis of CLN2 disease as determined by TPP1 enzyme activity (dried blood spot) in the fibroblasts and leukocytes available at Screening - Quantitative clinical assessment of the Hamburg motor-language aggregate score 3-6 at Screening on CLN2 disease motor-language scale, as defined in the Ratings Assessment Guideline - < 18 years of age at the time of informed consent - Written informed consent from parent or legal guardian and assent form subject, if appropriate - Males and females who are of reproductive age should practice true abstinence, defined as no sexual activity, during the study and for 6 months after the study has been completed (or withdrawal from the study). If sexually active and not practicing true abstinence, males and females of reproductive age must use a highly effective method of contraception while participating in the study. - Ability to comply with protocol required assessments (ICV implantation, drug administration, laboratory sample collection, EEG, ECG, MRI, etc.) Exclusion Criteria: - Presence of another inherited neurological disease, e.g., other forms of CLN or seizures unrelated to CLN2 disease (patients with febrile seizures may be eligible) - Presence of another neurological illness that may have caused cognitive decline (e.g., trauma, meningitis, hemorrhage) or interference with disease rating (autism) before Screening - Presence of percutaneous feeding tube placement prior to enrollment - Has received stem cell, gene therapy, or ERT - Presence of contraindications for neurosurgery (e.g., congenital heart disease, severe respiratory impairment, or clotting abnormalities) - Presence of contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip in the eye, aneurysm clip in the brain) - Episode of generalized motor status epilepticus within 4 weeks before the First Dose visit - Severe infection (e.g., pneumonia, pyelonephritis, or meningitis) within 4 weeks before the First Dose visit (enrollment may be postponed) - Presence of ventricular abnormality (hydrocephalus, malformation) - Presence of ventricular shunt - Has known hypersensitivity to any of the components of BMN 190 - Has received any investigational mediation within 30 days before the first infusion of study drug or is scheduled to receive any investigational drug other than BMN 190 during the course of the study - Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's well being, safety, or clinical interpretability - Pregnancy any time during the study; a female subject judged by the investigator to be of childbearing potential will be tested for pregnancy |
Country | Name | City | State |
---|---|---|---|
Germany | Universitaetsklinikum Hamburg-Eppendorf | Hamburg | |
Italy | Children's Hospital Bambino Gesù,IRCCS | Rome | Piazza |
United Kingdom | Great Ormond Street Childrens Hospital | London | |
United States | Nationwide Children's Hospital | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
BioMarin Pharmaceutical |
United States, Germany, Italy, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and severity of adverse events as assessed by CTCAE v 4.0 | Up to 144 weeks + 6 month follow up post last study treatment | ||
Primary | Change in the 0-6-point Motor/Language (ML) score on the Hamburg CLN2 rating scale | Up to 144 weeks + 6 month follow up post last study treatment | ||
Primary | Immunogenicity of BMN 190 in CSF and serum | Up to 144 weeks | ||
Secondary | Change in the total Hamburg CLN2 rating scale | Up to 144 weeks + 6 month follow up post last study treatment | ||
Secondary | Change in clinical laboratory tests | Up to 144 weeks | ||
Secondary | Change in CSF and Plasma laboratory parameters | Up to 144 weeks | ||
Secondary | Vital signs | Up to 144 weeks + 6 month follow up post last study treatment | ||
Secondary | Physical examination | Up to 144 weeks + 6 month follow up post last study treatment | ||
Secondary | Neurological examinations | Up to 144 weeks | ||
Secondary | Electrocardiogram (ECG), 3 or 5-lead, 12-lead | Up to 144 weeks + 6 month follow up post last study treatment | ||
Secondary | Change in Brain Volumes as Assessed by Cranial Magnetic Resonance Imaging (MRI) | Up to 144 weeks | ||
Secondary | Assess time to disease manifestation for asymptomatic patients | Up to 144 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02254863 -
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
|
Phase 1 | |
Completed |
NCT01907087 -
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03307304 -
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
|
||
Active, not recruiting |
NCT03770572 -
Gene Therapy for Children With CLN3 Batten Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT06203106 -
NYSCF Scientific Discovery Biobank
|
||
Completed |
NCT00151268 -
Genotype - Phenotype Correlations of LINCL
|
N/A | |
Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
Completed |
NCT01035424 -
Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
|
||
Completed |
NCT00151216 -
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis
|
Phase 1 | |
Active, not recruiting |
NCT04273243 -
Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer
|
||
Recruiting |
NCT03285425 -
Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae
|
||
Completed |
NCT00176904 -
Stem Cell Transplant for Inborn Errors of Metabolism
|
Phase 2/Phase 3 | |
Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
Completed |
NCT02485899 -
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05174039 -
An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT01698229 -
Collection of Cerebrospinal Fluid in Healthy Children
|
N/A | |
Enrolling by invitation |
NCT03862274 -
Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease
|
||
Recruiting |
NCT01873924 -
Clinical and Neuropsychological Investigations in Batten Disease
|
||
Completed |
NCT01161576 -
Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)
|
Phase 1 | |
Recruiting |
NCT04613089 -
Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database
|